Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRAEC
NCT04552704Phase 2Terminated
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised trial of efprezimod alfa in immune-related adverse events (irAEs) (3 arms). Primary endpoints: Number of Participants With New Adverse Event of Grade >= 3 at 60 days, Recovery Rate at 42 days and 1 more. Started Oct 2020; status: terminated.
02
Drugs
efprezimod alfa
03
Conditions
immune-related adverse events (irAEs)
Beyond the preview
Go deeper on NCT04552704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552704.